In this video from the virtual American Society of Retina Specialists meeting, Peter K. Kaiser, MD, discusses AXT107, a synthetic peptide designed to treat wet age-related macular degeneration and macular edema.
Soon to enter clinical trials, AXT107 (AsclepiX Therapeutics) develops a gel-like depot when injected, which may lead to extended durability.
Uncategorized